FDA OKs Bionovo breast cancer drug test
The Food and Drug Administration accepted Bionovo Inc.'s protocol for an early-stage clinical trial of BZL101, a drug for metastatic breast cancer. Emeryville-based Bionovo (OTCBB: BNVI) said Tuesday that the Phase I/II trial will be run at 10 centers in the United States. The company will enroll the first patients in the trial next year in the first quarter. --Click the title of this post to read the full article from its source--